{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:11:43Z","timestamp":1774991503718,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a notoriously lethal malignancy with high epithelial-mesenchymal transition (EMT) baseline. EMT is associated with enhanced cell plasticity and contributes to tumor adaption and evolution. EMT programs fuel PDAC invasion, metastasis, and treatment resistance, but directly targeting EMT has yielded limited clinical benefits. Transdifferentiation therapy that exploits cell plasticity and redirects malignant cell fate offers an orthogonal approach beyond pathway inhibition. To validate the feasibility of transdifferentiation in epithelial malignancies such as PDAC, we applied an adipogenesis protocol in seven human PDAC cell lines and distinguished AsPC-1 with intensified adipocyte features (intracellular lipid droplets accumulation, elevated adiponectin, CEBPA, PPARG, FABP4 expression). AsPC-1 was converted into adipocyte-like, post-mitotic cells with lipometabolic (enhanced adiponectin secretion and lipolysis) and phenotypic reprogramming (proliferation inhibition, G1 cell cycle arrest, and EMT key transcription factors downregulation). Multi-omics showed global chromatin compaction and transcriptome-wide repression of EMT and metastatic programs in induced AsPC-1 cells, with suppressed MMPs and TGF-\u03b2, indicating diminished metastatic potential. Therefore, we further evaluated the possibility of clinical translation by murine orthotopic and hepatic metastasis models, finding adipogenesis induction reduced primary tumor burden and slowed metastatic progression. The adipocyte-like phenotype in vivo was sustained through one-month observation period following induction drug withdrawal. This study establishes a plasticity-oriented \u201cconvert-instead-of-kill\u201d strategy for EMT-high PDAC, suggesting a potential for future studies to investigate rational combinations (e.g., transdifferentiation therapy combined with targeted or immunotherapy) to exploit lineage conversion.<\/jats:p>","DOI":"10.1038\/s41419-026-08613-4","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:34:35Z","timestamp":1774020875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adipogenic transdifferentiation reprograms EMT-high PDAC cells into a post-mitotic adipocyte-like state and limits metastasis"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5220-5283","authenticated-orcid":false,"given":"Yunzhen","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixiu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musitaba","family":"Mutailifu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziguli","family":"Tulamaiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8306-0639","authenticated-orcid":false,"given":"Xue-Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-223X","authenticated-orcid":false,"given":"Zhi-Gang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"8613_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"8613_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41571-025-01019-9","volume":"22","author":"SB Dreyer","year":"2025","unstructured":"Dreyer SB, Beer P, Hingorani SR, Biankin AV. Improving outcomes of patients with pancreatic cancer. Nat Rev Clin Oncol. 2025;22:439\u201356.","journal-title":"Nat Rev Clin Oncol"},{"key":"8613_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326:851\u201362.","journal-title":"JAMA"},{"key":"8613_CR4","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186:1729\u201354.","journal-title":"Cell"},{"key":"8613_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.semcancer.2025.06.007","volume":"114","author":"A J Jeiroshi","year":"2025","unstructured":"J Jeiroshi A, Deng J, Xu Z, Comandatore A, Xu G, Glaviano A, et al. Navigating the paradox of senescence and chemoresistance in pancreatic cancer. Semin Cancer Biol. 2025;114:60\u201372.","journal-title":"Semin Cancer Biol"},{"key":"8613_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:7\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8613_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17:527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"8613_CR8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1053\/j.gastro.2011.04.050","volume":"141","author":"I Houbracken","year":"2011","unstructured":"Houbracken I, de Waele E, Lardon J, Ling Z, Heimberg H, Rooman I, et al. Lineage tracing evidence for transdifferentiation of acinar to duct cells and plasticity of human pancreas. Gastroenterology. 2011;141:731\u201341.","journal-title":"Gastroenterology"},{"key":"8613_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56493-7","volume":"16","author":"AT Schneider","year":"2025","unstructured":"Schneider AT, Koppe C, Crouchet E, Papargyriou A, Singer MT, B\u00fcttner V, et al. A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Nat Commun. 2025;16:1765.","journal-title":"Nat Commun"},{"key":"8613_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S2468-1253(23)00064-X","volume":"8","author":"MS Petrov","year":"2023","unstructured":"Petrov MS. Fatty change of the pancreas: the Pandora\u2019s box of pancreatology. Lancet Gastroenterol Hepatol. 2023;8:671\u201382.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"8613_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1148\/radiology.194.2.7824726","volume":"194","author":"S Matsumoto","year":"1995","unstructured":"Matsumoto S, Mori H, Miyake H, Takaki H, Maeda T, Yamada Y, et al. Uneven fatty replacement of the pancreas: evaluation with CT. Radiology. 1995;194:453\u20138.","journal-title":"Radiology"},{"key":"8613_CR12","first-page":"748","volume":"35","author":"G Targher","year":"2012","unstructured":"Targher G, Rossi AP, Zamboni GA, Fantin F, Antonioli A, Corzato F, et al. Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals. J Endocrinol Investig. 2012;35:748\u201353.","journal-title":"J Endocrinol Investig"},{"key":"8613_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature21064","volume":"542","author":"G Genovese","year":"2017","unstructured":"Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, et al. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017;542:362\u20136.","journal-title":"Nature"},{"key":"8613_CR14","first-page":"320","volume":"35","author":"CJ David","year":"2016","unstructured":"David CJ, Huang Y-H, Chen M, Su J, Zou Y. TGF-\u03b2 tumor suppression through a lethal EMT. Cell. 2016;35:320\u201330.","journal-title":"Cell"},{"key":"8613_CR15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/s41586-025-08671-2","volume":"640","author":"L Perelli","year":"2025","unstructured":"Perelli L, Zhang L, Mangiameli S, Giannese F, Mahadevan KK, Peng F, et al. Evolutionary fingerprints of epithelial-to-mesenchymal transition. Nature. 2025;640:1083\u201392.","journal-title":"Nature"},{"key":"8613_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature16064","volume":"20","author":"X Zheng","year":"2015","unstructured":"Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. EMT program is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;20:525\u201330.","journal-title":"Nature"},{"key":"8613_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500\u20133.","journal-title":"Nat Med"},{"key":"8613_CR18","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1158\/2159-8290.CD-20-1826","volume":"12","author":"R Maddipati","year":"2022","unstructured":"Maddipati R, Norgard RJ, Baslan T, Rathi KS, Zhang A, Saeid A, et al. MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma. Cancer Discov. 2022;12:542\u201361.","journal-title":"Cancer Discov"},{"key":"8613_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1053\/j.gastro.2020.09.010","volume":"160","author":"K Feldmann","year":"2021","unstructured":"Feldmann K, Maurer C, Peschke K, Teller S, Schuck K, Steiger K, et al. Mesenchymal plasticity regulated by Prrx1 drives aggressive pancreatic cancer biology. Gastroenterology. 2021;160:346\u2013.e24.","journal-title":"Gastroenterology"},{"key":"8613_CR20","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/2159-8290.CD-24-0137","volume":"14","author":"S Benitz","year":"2024","unstructured":"Benitz S, Steep A, Nasser MM, Preall J, Mahajan UM, McQuithey H, et al. ROR2 regulates cellular plasticity in pancreatic neoplasia and adenocarcinoma. Cancer Discov. 2024;14:2162\u201382.","journal-title":"Cancer Discov"},{"key":"8613_CR21","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2022.07.005","volume":"163","author":"T Baba","year":"2022","unstructured":"Baba T, Finetti P, Lillemoe KD, Warshaw AL, Fern\u00e1ndez-Del Castillo C, Liss AS. A lesson in transcriptional plasticity: classical identity is silenced, but not lost, in pancreatic ductal adenocarcinoma cell lines. Gastroenterology. 2022;163:1450\u2013.e3.","journal-title":"Gastroenterology"},{"key":"8613_CR22","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","volume":"184","author":"S Raghavan","year":"2021","unstructured":"Raghavan S, Winter PS, Navia AW, Williams HL, DenAdel A, Lowder KE, et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021;184:6119\u20136137.e26.","journal-title":"Cell"},{"key":"8613_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood.V72.2.567.567","volume":"72","author":"ME Huang","year":"1988","unstructured":"Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567\u201372.","journal-title":"Blood"},{"key":"8613_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccell.2018.12.002","volume":"35","author":"D Ishay-Ronen","year":"2019","unstructured":"Ishay-Ronen D, Diepenbruck M, Kalathur RKR, Sugiyama N, Tiede S, Ivanek R, et al. Gain fat\u2014lose metastasis: converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell. 2019;35:17\u201332.","journal-title":"Cancer Cell"},{"key":"8613_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.cell.2017.06.035","volume":"170","author":"D Kopinke","year":"2017","unstructured":"Kopinke D, Roberson EC, Reiter JF. Ciliary hedgehog signaling restricts injury-induced adipogenesis. Cell. 2017;170:340\u2013351.e12.","journal-title":"Cell"},{"key":"8613_CR26","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1194\/jlr.R046441","volume":"55","author":"QA Wang","year":"2014","unstructured":"Wang QA, Scherer PE, Gupta RK. Improved methodologies for the study of adipose biology: insights gained and opportunities ahead. J Lipid Res. 2014;55:605\u201324.","journal-title":"J Lipid Res"},{"key":"8613_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41586-022-04888-7","volume":"607","author":"L Lan","year":"2022","unstructured":"Lan L, Evan T, Li H, Hussain A, Ruiz EJ, Zaw Thin M, et al. GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. Nature. 2022;607:163\u20138.","journal-title":"Nature"},{"key":"8613_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15:129.","journal-title":"J Hematol Oncol"},{"key":"8613_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S1097-2765(00)80306-8","volume":"3","author":"Z Wu","year":"1999","unstructured":"Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE, et al. Cross-regulation of C\/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell. 1999;3:151\u20138.","journal-title":"Mol Cell"},{"key":"8613_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1101\/gad.948702","volume":"16","author":"ED Rosen","year":"2002","unstructured":"Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, et al. C\/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 2002;16:22\u201326.","journal-title":"Genes Dev"},{"key":"8613_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41392-024-02030-9","volume":"9","author":"Y Chen","year":"2024","unstructured":"Chen Y, Liang R, Li Y, Jiang L, Ma D, Luo Q, et al. Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application. Signal Transduct Target Ther. 2024;9:340.","journal-title":"Signal Transduct Target Ther"},{"key":"8613_CR32","doi-asserted-by":"publisher","first-page":"e2411887121","DOI":"10.1073\/pnas.2411887121","volume":"122","author":"ML Perkins","year":"2025","unstructured":"Perkins ML, Crocker J, Tka\u010dik G. Chromatin enables precise and scalable gene regulation with factors of limited specificity. Proc Natl Acad Sci USA. 2025;122:e2411887121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8613_CR33","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","volume":"31","author":"AM Varghese","year":"2025","unstructured":"Varghese AM, Perry MA, Chou JF, Nandakumar S, Muldoon D, Erakky A, et al. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat Med. 2025;31:466\u201377.","journal-title":"Nat Med"},{"key":"8613_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21:341\u201352.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8613_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrc.2015.6","volume":"16","author":"S Seton-Rogers","year":"2016","unstructured":"Seton-Rogers S. Epithelial-mesenchymal transition: untangling EMT\u2019s functions. Nat Rev Cancer. 2016;16:1.","journal-title":"Nat Rev Cancer"},{"key":"8613_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41556-022-01045-0","volume":"25","author":"J Cui","year":"2023","unstructured":"Cui J, Zhang C, Lee JE, Bartholdy BA, Yang D, Liu Y, et al. MLL3 loss drives metastasis by promoting a hybrid epithelial-mesenchymal transition state. Nat Cell Biol. 2023;25:145\u201358.","journal-title":"Nat Cell Biol"},{"key":"8613_CR37","doi-asserted-by":"crossref","unstructured":"Kawai M, Fukuda A, Ikeda M, Iimori K, Mizukoshi K, Iwane K, et al. Polybromo 1\/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. J Clin Investig. 2025;135:e177533.","DOI":"10.1172\/JCI177533"},{"key":"8613_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8677","volume":"6","author":"R Russell","year":"2015","unstructured":"Russell R, Perkhofer L, Liebau S, Lin Q, Lechel A, Feld FM, et al. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. Nat Commun. 2015;6:7677.","journal-title":"Nat Commun"},{"key":"8613_CR39","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1158\/0008-5472.CAN-23-3578","volume":"84","author":"M Wirth","year":"2024","unstructured":"Wirth M, Schneider G. A hypoxia-epigenetics axis drives EMT in pancreatic cancer. Cancer Res. 2024;84:1739\u201341.","journal-title":"Cancer Res"},{"key":"8613_CR40","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1158\/0008-5472.CAN-22-2945","volume":"84","author":"BA Brown","year":"2024","unstructured":"Brown BA, Myers PJ, Adair SJ, Pitarresi JR, Sah-Teli SK, Campbell LA, et al. A histone methylation-MAPK Signaling axis drives durable epithelial-mesenchymal transition in hypoxic pancreatic cancer. Cancer Res. 2024;84:1764\u201380.","journal-title":"Cancer Res"},{"key":"8613_CR41","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/ncb3050","volume":"16","author":"Y Wang","year":"2014","unstructured":"Wang Y, Bu F, Royer C, Serres S, Larkin JR, Soto MS, et al. ASPP2 controls epithelial plasticity and inhibits metastasis through \u03b2-catenin-dependent regulation of ZEB1. Nat Cell Biol. 2014;16:1092\u2013104.","journal-title":"Nat Cell Biol"},{"key":"8613_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405083","volume":"12","author":"S Huang","year":"2025","unstructured":"Huang S, Qin X, Fu S, Hu J, Jiang Z, Hu M, et al. STAMBPL1\/TRIM21 balances AXL stability impacting mesenchymal phenotype and immune response in KIRC. Adv Sci. 2025;12:e2405083.","journal-title":"Adv Sci"},{"key":"8613_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-021-00551-0","volume":"19","author":"MS Petrov","year":"2022","unstructured":"Petrov MS, Taylor R. Intra-pancreatic fat deposition: bringing hidden fat to the fore. Nat Rev Gastroenterol Hepatol. 2022;19:153\u201368.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8613_CR44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/BF02796382","volume":"18","author":"WH Chen","year":"1982","unstructured":"Chen WH, Horoszewicz JS, Leong SS, Shimano T, Penetrante R, Sanders WH, et al. Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro. 1982;18:24\u201334.","journal-title":"In Vitro"},{"key":"8613_CR45","doi-asserted-by":"crossref","unstructured":"Yu Q, Dong Y, Wang X, Su C, Zhang R, Xu W, et al. Pharmacological induction of MHC-I expression in tumor cells revitalizes T cell antitumor immunity. JCI insight. 2024;9:e177788.","DOI":"10.1172\/jci.insight.177788"},{"key":"8613_CR46","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","volume":"188","author":"L Zhong","year":"2025","unstructured":"Zhong L, Gan L, Wang B, Wu T, Yao F, Gong W, et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell. 2025;188:1119\u20131136.e23.","journal-title":"Cell"},{"key":"8613_CR47","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","volume":"25","author":"P Lito","year":"2014","unstructured":"Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014;25:697\u2013710.","journal-title":"Cancer Cell"},{"key":"8613_CR48","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","volume":"50","author":"JR Infante","year":"2014","unstructured":"Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer. 2014;50:2072\u201381.","journal-title":"Eur J Cancer"},{"key":"8613_CR49","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1136\/gutjnl-2024-333408","volume":"74","author":"S Zhang","year":"2025","unstructured":"Zhang S, Deng S, Liu J, Liu S, Chen Z, Liu S, et al. Targeting MXD1 sensitises pancreatic cancer to trametinib. Gut. 2025;74:1262\u201378.","journal-title":"Gut"},{"key":"8613_CR50","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556\u2013W560.","journal-title":"Nucleic Acids Res"},{"key":"8613_CR51","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.cmet.2016.12.008","volume":"25","author":"M Sakaguchi","year":"2017","unstructured":"Sakaguchi M, Fujisaka S, Cai W, Winnay JN, Konishi M, O\u2019Neill BT, et al. Adipocyte dynamics and reversible metabolic syndrome in mice with an inducible adipocyte-specific deletion of the insulin receptor. Cell Metab. 2017;25:448\u201362.","journal-title":"Cell Metab"},{"key":"8613_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-15-182","volume":"15","author":"H Jiang","year":"2014","unstructured":"Jiang H, Lei R, Ding S-W, Zhu S. Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. BMC Bioinformatics. 2014;15:182.","journal-title":"BMC Bioinformatics"},{"key":"8613_CR53","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.12688\/f1000research.15931.1","volume":"7","author":"SW Wingett","year":"2018","unstructured":"Wingett SW, Andrews S. FastQ screen: a tool for multi-genome mapping and quality control. F1000Research. 2018;7:1338.","journal-title":"F1000Research"},{"key":"8613_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"8613_CR55","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nbt.3122","volume":"33","author":"M Pertea","year":"2015","unstructured":"Pertea M, Pertea GM, Antonescu CM, Chang T-C, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33:290\u20135.","journal-title":"Nat Biotechnol"},{"key":"8613_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"8613_CR57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27\u201330.","journal-title":"Nucleic Acids Res"},{"key":"8613_CR58","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/bioinformatics\/btl140","volume":"22","author":"A Alexa","year":"2006","unstructured":"Alexa A, Rahnenf\u00fchrer J, Lengauer T. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics. 2006;22:1600\u20137.","journal-title":"Bioinformatics"},{"key":"8613_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18035-1","volume":"11","author":"M Bentsen","year":"2020","unstructured":"Bentsen M, Goymann P, Schultheis H, Klee K, Petrova A, Wiegandt R, et al. ATAC-seq footprinting unravels kinetics of transcription factor binding during zygotic genome activation. Nat Commun. 2020;11:4267.","journal-title":"Nat Commun"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08613-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08613-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08613-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:02:06Z","timestamp":1774987326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08613-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8613"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08613-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Research Ethics Committee of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University (ID: 2015037). The ethics committee mandates a maximal tumor burden of less than 5% of normal body weight of murine models, and we confirmed that all tumor samples collected in this study complied with this requirement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"330"}}